Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. uri icon

authors

  • Shipman, William D
  • Singh, Katelyn
  • Cohen, Jeffrey M
  • Leventhal, Jonathan
  • Damsky, William
  • Tomayko, Mary M

publication date

  • August 24, 2023